Other

Taigen Biotechnology Company, Ltd.

Taigen Biotechnology

Hua-Chien Chen

Shu-Jen Chen

Chi-Feng Yen

Ying-Huey Huang

Gholam Hossein Hakimelahi

Yibin Xiang

Kak-Shan Shia

Chi-Hsin Richard King

Chien-Huang Wu

Ching-Cheng Wang

Jia-Liang Zhu

Jen-Hao Cheng

Pei-Jia Yang

Ying-Ja Chen

This disclosure relates to systems and methods that identify, predict, and rank immunogenic T-cell epitopes. In particular, this disclosure identifies epitopes that arose from disease-associated mutations, wherein the epitopes are predicted to elicit immune response from T cells. Specifically, this disclosure simultaneously considers peptide-level information, including MHC Class I and II presentation, helper and cytotoxic T cell response and sample-level information, including mutation clonality and MHC allele dosage. In some embodiment, the systems and methods are used for personalized treatment of cancers.

Ranking system for immunogenic cancer-specific epitopes

This invention relates to methods for treating retinopathy and repairing tissue damage. The methods include administering to a subject in need thereof an effective amount of one or more compounds of the following formula. Each variable in this formula is defined in the specification. 

Polyamine compounds

This invention relates to a method for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, or tissue injuries. The method includes administering to a subject in need thereof an effective amount of one or more compounds of the following formula. Each variable in this formula is defined in the specification. 

Polyamine compounds for treating chemokine receptor mediated diseases

Growing community of inventors

Taipei, Taiwan

Hua-Chien Chen